Filtered By:
Countries: Israel Health

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 143 results found since Jan 2013.

A new hormonal therapy for prostate cancer is under expedited FDA review
In June, the US Food and Drug Administration (FDA) launched an accelerated review of a promising new drug for advanced prostate cancer. Called relugolix, it suppresses testosterone and other hormones that speed the cancer’s growth. If approved, this new type of hormonal therapy is expected to set a new standard of care for the disease. Doctors give hormonal therapies when a man’s tumor is metastasizing (spreading beyond the prostate), or if his PSA levels start rising after surgery or radiation. The most commonly used hormonal therapies, called LHRH agonists, will eventually lower testosterone levels in blood. ...
Source: Harvard Health Blog - July 13, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs

Wednesday Bible Study: The holy swag
I said at the beginning that nobody reads Leviticus. It ' s mostly boring and extremely weird, offering little that is meaningful to modern sensibilities. Some fragments of ritual or practice survive in orthodox Judaism, but they are largely removed from their original context. The most important survival is probably the liturgical calendar, which we will get to shortly. In Leviticus 22, however, we return to rules of the sacrifice, which have no moral resonance and theologically make God seem like an anal compulsive nut. (That ' s the least of his psychological disorders. Just  wait till we get to the book of Numbers...
Source: Stayin' Alive - June 24, 2020 Category: American Health Source Type: blogs

New drugs approved for advanced BRCA-positive prostate cancer
Defective BRCA genes are well known for their ability to cause breast and ovarian cancers in women. But these same gene defects are also strong risk factors for aggressive prostate cancer in men. About 10% of men with metastatic prostate cancer — meaning cancer that is spreading away from the prostate — test positive for genetic mutations in BRCA genes. Fortunately, these cancers can be treated with new types of personalized therapies. In May, the FDA approved two new drugs specifically for men with BRCA-positive metastatic prostate cancer that has stopped responding to other treatments. One of the drugs, called rucapa...
Source: Harvard Health Blog - June 15, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs

Combining different biopsies limits uncertainty in prostate cancer diagnosis
Are prostate cancer biopsies reliably accurate? Not always. The most common method, called a systematic biopsy, sometimes misses tumors, and it can also misclassify cancer as being either more or less aggressive than it really is. During systematic biopsy, a doctor takes 12 evenly-spaced samples of the prostate, called cores, while looking at the gland with an ultrasound machine. A new method, called MRI-targeted biopsy, guides doctors to suspicious abnormalities in the prostate, and emerging evidence suggests that it’s better at detecting high-grade, aggressive tumors that need immediate treatment. These biopsies re...
Source: Harvard Health Blog - May 26, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Diagnosis Health Prostate Knowledge HPK Source Type: blogs

Sunday Sermonette: A plague upon your house!
Today ' s excerpt is fairly short, which gives me an opportunity to say something about the origin of the Tanakh, and particularly the Torah/Pentateuch. The Torah is thought to have first been compiled around 600 BC, or perhaps considerably later. However, no documents anywhere near that old have survived. The text which is the basis of all modern Torahs and Christian Bibles is the so-called Masoretic text, which dates to around 600 AD but the oldest extant copies were made in the 9th Century. A somewhat older source is a Greek translation called the Septuagint, which differs in some mostly minor ways. The so-called Dead S...
Source: Stayin' Alive - May 10, 2020 Category: American Health Source Type: blogs

New radiation therapies keep advanced prostate cancer in check
Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer evidence shows that treating the metastatic tumors directly with radiation can produce better results. In March, researchers published the latest study that supports this approach. Based at Johns Hopkins University School of Medicine in Baltimore, the team used a method for delivering power...
Source: Harvard Health Blog - April 28, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

New study compares long-term side effects from different prostate cancer treatments
Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights. Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal status of nearly 2,000 men after they had been treated for prostate cancer, or monitored with active surveillance (which entails checking the tumor periodically and treating it only if it begins to grow). Cancers in all the men were still confined to the p...
Source: Harvard Health Blog - February 27, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs

African American and white men who receive comparable treatments for prostate cancer have similar survival
Last year, we reported on two studies showing that African American men respond at least as well as white men to prostate cancer treatments given in clinical trials. Nationally, African Americans with prostate cancer are more than twice as likely to die of the disease as their white counterparts, and that has fueled speculation that genetic or biological factors put them at greater risk. But according to this new research, the survival difference disappears when men of either race get the same cutting-edge treatments. Now scientists are reporting that African American and white men with prostate cancer live equally as long...
Source: Harvard Health Blog - February 13, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs

Reinventing CDS Requires Humility in the Face of Overwhelming Complexity
Paul Cerrato and I have created a new book,Reinventing Clinical Decision Support, our first to be published about Platform thinking.  Although it is being published during my tenure at Mayo Clinic, it is not endorsed by Mayo Clinic and represents the personal opinions of Paul and me.  Below is the preface.In our last book, on mobile health(1),  we wrote about the power of words such as cynicism, optimism, and transformation. Another word with powerful connotations is misdiagnosis. To a patient whose condition remains undetected, it is a source of frustration and anger. To a physician or nurse who has be...
Source: Life as a Healthcare CIO - December 30, 2019 Category: Information Technology Source Type: blogs

Researchers urge prostate cancer screening for men with BRCA gene defects
Prostate cancer screening with the prostate-specific antigen (PSA) test has been criticized for flagging too many slow-growing tumors that might never be life-threatening. But some men have inherited gene defects that boost their risk of developing prostate cancers that can be quite aggressive. Is PSA screening particularly well-suited for these genetically defined groups? New research suggests the answer is yes. In November, a team of British scientists released highly anticipated findings from a study of PSA screening in men with defects in a pair of important genes called BRCA1 and BRCA2. Better known for increasing the...
Source: Harvard Health Blog - December 20, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Prostate Knowledge Screening HPK Source Type: blogs

RSNA 2019 AI Round-Up
Shah Islam Hugh Harvey By HUGH HARVEY, MBBS and SHAH ISLAM, MBBS AI in medical imaging entered the consciousness of radiologists just a few years ago, notably peaking in 2016 when Geoffrey Hinton declared radiologists’ time was up, swiftly followed by the first AI startups booking exhibiting booths at RSNA. Three years on, the sheer number and scale of AI-focussed offerings has gathered significant pace, so much so that this year a decision was made by the RSNA organising committee to move the ever-growing AI showcase to a new space located in the lower level of the North Hall. In some ways it made sense to offe...
Source: The Health Care Blog - December 10, 2019 Category: Consumer Health News Authors: Christina Liu Tags: Artificial Intelligence Health Tech Start-Ups AI Hugh Harvey Radiology RSNA RSNA 2019 RSNA19 Shah Islam Source Type: blogs

Most men can hold off on radiation after prostate cancer surgery
Decisions about follow-up care after prostate cancer surgery sometimes involve a basic choice. If the cancer had features that predict it could return, doctors will likely recommend radiation therapy. But when should a man get that treatment? Should he get the radiation right away, even if there’s no evidence of cancer in the body (this is called adjuvant radiation)? Or should he opt for “salvage” radiation, which is given only if his blood levels of prostate-specific antigen (PSA) begin to climb? Since prostate cancer cells release PSA, the levels should be nondetectable after surgery. If they increase, that means t...
Source: Harvard Health Blog - December 2, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Treatments HPK Source Type: blogs

Darolutamide approved for nonmetastatic castration-resistant prostate cancer
Sometimes after finishing prostate cancer treatment, men get an unwelcome surprise: their prostate-specific antigen (PSA) levels creep higher, suggesting tumors too small to be seen lurk somewhere in the body. This leads to several options. Doctors can continue to monitor a man’s condition with imaging scans. Or, given the anxiety associated with rising PSA, they might try to lower the levels with chemically “castrating” drugs that inhibit testosterone, a hormone that makes prostate tumors grow faster. Following that treatment, called androgen deprivation therapy (ADT), PSA generally declines and may become undetecta...
Source: Harvard Health Blog - November 22, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Treatments HPK Source Type: blogs

From Theranos To Google Glass: The Biggest Flops In Digital Health
The tech start-up scene, investors, and news-reading audiences reward great stories on the edge of human capabilities – sometimes even on the boundary of science and science fiction – with their attention, money, or invested energy. However, sometimes marketing machines are better than actual technologies, and the ‘little bubbles’ around companies burst. Here, we collected the most promising digital health ideas and companies over the years that proved to be the greatest flops in medical innovation so far. ‘Big little bubbles’ that turned into digital health failures Humans love great sto...
Source: The Medical Futurist - October 2, 2019 Category: Information Technology Authors: nora Tags: Future of Medicine Health Sensors & Trackers AI artificial intelligence companies development device digital digital health digital health market gadgets google google glass hype Innovation invention medical device promis Source Type: blogs

Common hormonal treatments linked to abnormal heart rhythms and sudden death in men being treated for prostate cancer
Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. In 2004, Dr. Marc Garnick, Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org, reported that in some men, an ADT drug called aberelix lengthens the time it tak...
Source: Harvard Health Blog - September 20, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs